All Quantitative Report

Argus•February 17, 2021

EXEL: Lowering target price to $23.00

Symbols

Sector(s)

Healthcare

Rating

Current Price

$23.71

Price Target

Earnings Estimate

Summary

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercial

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level

Actions

Download Full Report

Related Reports

NBIX: Raising target price to $147.00
Apr 24, 2024 •
NBIX
HALO: Raising target price to $41.00
Apr 24, 2024 •
HALO
The Argus Innovation Model Portfolio
Apr 23, 2024 •
GOOGL, AMAT, AAPL, ANET, CVX, ADI, AXON, URI, COST, V, LLY, SPGI, PANW, META, NVDA, SYK, BSX, ORCL, PWR, CBOE, MCK, NOW, ADBE, LYFT, SCHW, MCHP, ISRG, AMZN, ODFL, CRM
Technical Assessment: Neutral in the Intermediate-Term
Apr 22, 2024 •
CVX, PFE
Technical Assessment: Neutral in the Intermediate-Term
Apr 19, 2024 •
AA, LLY

View more related reports